secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-204944
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA reports positive Phase 2/3 darovasertib trial; Q1 net loss $98.5M, cash $973M
--------------------------------------------------------------------------------

- Phase 2/3 OptimUM-02 met primary endpoint: 58% risk reduction in PFS (HR 0.42, p<0.0001), median PFS 6.9 vs 3.1 months.
- NDA submission for darovasertib under FDA RTOR planned H2 2026; complete data at ASCO 2026.
- Cash equivalents and marketable securities $972.9M as of March 31, 2026; runway unchanged into 2030.
- Net loss for Q1 2026 was $98.5M vs $83.3M in Q4 2025; R&D expenses $95.7M.
- Appointed Dr. Theodora Ross as Chief Development Officer in February 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/0001193125-26-204944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/idya-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-204944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer